Defibrillators In Nonischemic Cardiomyopathy Treatment Evaluation

Below is result for Defibrillators In Nonischemic Cardiomyopathy Treatment Evaluation in PDF format. You can download or read online all document for free, but please respect copyrighted ebooks. This site does not host PDF files, all document are the property of their respective owners.

Wearable Cardio Defibrillator and Automatic External

5. Nonischemic dilated cardiomyopathy (DCM), LVEF less than or equal to 35%, in NYHA functional Class II or III. 6. LV dysfunction due to prior MI, at least 40 days post-MI, LVEF less than 30%, in NYHA functional Class I 7. Nonsustained VT due to prior MI, LVEF less than 40%, and inducible VF or sustained VT at electrophysiological study 8.

Clinical Policy: External & Wearable Defibrillators for the

G. Either a documented prior myocardial infarction or dilated cardiomyopathy and a measured left ventricular ejection fraction less than or equal to 0.35. II. It is the policy of health plans affiliated with Centene Corporation that non-wearable automatic cardioverter defibrillators are medically necessary when meeting one of the following: A.

Wearable Cardioverter Defibrillators

See the Implantable Cardioverter Defibrillators Protocol for further information on ICDs. The wearable cardioverter defibrillator (WCD) is an external device intended to perform the same tasks as an ICD, without invasive procedures.

The Cholesterol Paradox in Heart Failure

cardiomyopathy. Hypercholesterolemia is a major risk factor for CAD. Statins (3-hydroxy-3-methyl-glutaryl-coen-zyme A reductase inhibitors) are highly effective in reducing low-density lipo-protein cholesterol levels by reducing the endogenous synthesis of cholester-ol. Statins have been shown to reduce mortality and morbidity in several large

Implantable Cardioverter Defibrillators. Prophylactic Use

Implantable Cardioverter Defibrillators-Ontario Health Technology Assessment Series 2005; Vol. 5, No. 14 7 Executive Summary Objective The use of implantable cardiac defibrillators (ICDs) to prevent sudden cardiac death (SCD) in patients resuscitated from cardiac arrest or documented dangerous ventricular arrhythmias (secondary prevention

Implantable Cardioverter Defibrillators

Jul 03, 2019 b) Ischemic cardiomyopathy with NYHA functional class I symptoms, a history of myocardial infarction at least 40 days before ICD treatment, and left ventricular ejection fraction of 30% or less; or c) Nonischemic dilated cardiomyopathy and left ventricular ejection fraction of 35% or less, after reversible causes have been excluded,

Title: Wearable Cardioverter Defibrillators

Treatment Defibrillators work by giving the heart a controlled electric shock, hopefully jolting it back into a regular rhythm. The implantable cardioverter defibrillator (ICD) has proven effective in reducing mortality for survivors of SCA and for patients with documented malignant ventricular arrhythmias.

Implantable Cardioverter Defibrillator - SuperCoder

4. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE); and 5. Amiodarone versus Implantable Defibrillator Randomized Trial (AMIOVIRT). The 2004 TEC Assessment made the following observations.

Last Review Status/Date - FEP Blue

4. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE); and 5. Amiodarone versus Implantable Defibrillator Randomized Trial (AMIOVIRT). The 2004 TEC Assessment made the following conclusions about the use of ICD devices. The use of ICD devices meets the TEC criteria in the prevention of sudden death from VT in patients

Wearable Cardioverter Defibrillator and Automatic External

Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations. Overview This Coverage Policy addresses the wearable cardioverter defibrillator, automatic external defibrillators

ORIGINAL INVESTIGATION Implantable Cardioverter

Implantable Cardioverter Defibrillators and Quality of Life Results From the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation Study Rod Passman, MD, MSCE; Haris Subacius, MA; Bernice Ruo, MD, MAS; Andi Schaechter, RN; Adam Howard, BA; Sam F. Sears, PhD; Alan Kadish, MD Background: The Defibrillators in Nonischemic Car-

Case Study - American College of Cardiology

patients with idiopathic dilated cardiomyopathy presenting with SCD-HeFT criteria? Am J Cardiol, 2012. 109(5): p. 729-35. 4. Zou, C.H., et al., Frequency and predictors of normalization of left ventricular ejection fraction in recent-onset nonischemic cardiomyopathy. Am J Cardiol, 2014. 113(10): p. 1705-10. 5.

070 Implantable Cardioverter Defibrillator

Ischemic cardiomyopathy with New York Heart Association (NYHA) functional Class II or Class III symptoms, a history of myocardial infarction at least 40 days before ICD treatment and left-ventricular ejection fraction of 35% or less; or Ischemic cardiomyopathy (IDCM) with NYHA functional Class I symptoms, a history of myocardial

Syncope - fmshk.org

ischaemic cardiomyopathy (CMP) is less profound and yet substantial. In the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial, ICD was shown to significantly reduce the risk of sudden death from arrhythmia. The reduction in total mortality has not reached statistical significance. 16

An implantable cardioverter-defibrillator for primary

analysis: Cardiomyopathy Trial (CAT), Amiodarone Versus Implantable Cardioverter-Defibrillator trial (AMIOVIRT), Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation Trial (DEFINITE), and DANISH [6, 9 11]. They are the only identified RCTs in which the experimental and control group were NICM. The baseline clinical

The incidence of malignant arrhythmia and death outcomes in

Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Lessons from the DEFINITE Trial - Cardiolatina

The Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial was a prospective, randomized multicenter trial of ICD therapy in 458 patients with a nonischemic dilated cardiomyopathy.1 The trial was designed based on the premise that: patients with nonischemic

CLINICIAN UPDATE - CiteSeerX

those with ischemic or nonischemic cardiomyopathy.6 Multiple clinical tri-Figure 1. Distribution of clinical status of individuals suffering sudden cardiac death (SCD). MI indicates myocardial infarction; AP, angina pectoris. From Myerburg RJ, Reddy V, Castellanos A. Indications for implantable cardioverter-defibrillators based on evidence and

Inappropriate Shocks Medtronic Data Show Effectiveness of

May 13, 2010 ³ Kadish A, Dyer A, Daubert JP, et al, for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. May 20, 2004;350(21):2151-2158. SOURCE: Medtronic, Inc. Medtronic, Inc. Public Relations

NCD 20.4 Implantable Cardiac Defibrillators (ICDs)

Mar 03, 2020 I50.22, I50.23, I50.41, I50.42, and I50.43) for patients with ischemic or nonischemic - cardiomyopathy are based on NCD language, which specifically adds this requirement. While CMS agrees that the NYHA classification of heart failure is a functional classification and may

Wearable Cardioverter Defibrillators

Mar 23, 2021 The most common reason will be a systemic infection that requires treatment before the ICD can be implanted. The wearable cardioverter defibrillator should only be used short-term while the temporary contraindication (eg, systemic infection) is being clinically managed. Once treatment is completed, the permanent ICD should be implanted. 2.

Prognostic Value and Temporal Behavior of the Planar QRS-T

The Defibrillators in Nonischemic Cardiomyopathy Treat-ment Evaluation (DEFINITE) trial was a prospective, ran-domized, multicenter trial of ICD therapy in patients with nonischemic cardiomyopathy.2 In this population, ICD ther-apy resulted in a significant reduction in sudden cardiac death and a trend toward decreased all-cause mortality. We

Wearable Cardioverter-Defibrillators Protocol

17. Kadish A, Schaechter A, Subacius H et al. Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter-defibrillators. J Am Coll Cardiol 2006; 47(12):2477-82. 18. Saltzberg MT, Szymkiewicz S, Bianco NR. Characteristics and outcomes of peripartum versus nonperipartum

Medical Coverage Policy Non-Wearable Automatic External

Survival after application of automatic external defibrillators before arrival of the emergency medical system: evaluation in the resuscitation outcomes consortium population of 21 million. J Am Coll Cardiol. 2010 Apr 20;55(16):1713-20 i ii This medical policy is made available to you for informational purposes only.

Effectiveness of Implantation of Cardioverter- Defibrillators

trials are the Cardiomyopathy Trial (CAT), the Amiodarone versus Implantable Defibrillator Randomized Trial (AMIOVIRT), the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE), the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), and the Danish Study (DANISH). Substantial heterogeneity among studies was inevitable.

042 Wearable Cardioverter Defibrillators

I25.5 Ischemic cardiomyopathy I25.89 Other forms of chronic ischemic heart disease I42.0 Dilated cardiomyopathy I42.1 Obstructive hypertrophic cardiomyopathy I42.2 Other hypertrophic cardiomyopathy I42.5 Other restrictive cardiomyopathy I42.8 Other cardiomyopathies I42.9 Cardiomyopathy, unspecified I47.0 Re-entry ventricular arrhythmia

Wearable Cardioverter Defibrillators Corporate Medical Policy

Feb 01, 2021 Ischemic cardiomyopathy with NYHA functional class I symptoms, a history of myocardial infarction at least 40 days before ICD treatment, and left ventricular ejection fraction of 30% or less; OR Nonischemic dilated cardiomyopathy and left ventricular ejection fraction of 35% or

Review Article Risk Stratification for Sudden Cardiac Death

Defibrillators in Non-ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial. DEFINITE compared the use of the ICD with standard oral medical therapy vs. medical therapy only of patients with NIDCM and NSVT. Inclusion criteria for the trial included EF <35%,

Implantable Cardioverter-Defibrillators for Primary

with nonischemic dilated cardiomyopathy (8-9), in 2004 the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) (10) trial started to change this view. In this study, 458 patients with nonischemic dilated cardiomyopathy, LVEF less than 36%, and premature ventricular

CLINICAL APPROPRIATENESS GUIDELINES

5. Nonischemic dilated cardiomyopathy when, following 90 days of GDMT, BOTH of the following (a and b) are still present a. Left ventricular ejection fraction (LVEF) ≤ 35% b. NYHA functional class II or III 6. Ischemic cardiomyopathy when ANY of the following (a-c) apply a.

MADIT Randomized Trial to Reduce Inappropriate Therapy (MADIT

Defibrillatorsin Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic c ardiomyopathy? Circulation 2006;113:776-782. 7.

2.02.506 Wearable Cardioverter-Defibrillators as a Bridge to

Ischemic cardiomyopathy with NYHA functional Class I symptoms, a history of myocardial infarction at least 40 days before ICD treatment, and left ventricular ejection fraction of 30% or less OR Nonischemic dilated cardiomyopathy (NIDCM) and left ventricular ejection fraction of 35% or

Implantable Cardioverter Defibrillator (ICD)

Nonischemic dilated cardiomyopathy, LVEF ≤ 49% Left ventricular non-compaction Hypertrophic cardiomyopathy Cardiac amyloidosis Tetralogy of Fallot with prior corrective surgery Unexplained syncope in individual with arrhythmogenic right ventricular cardiomyopathy

OHCA Guideline Wearable Cardioverter Defibrillator (WCD) and

2. Ischemic cardiomyopathy with NYHA functional class I symptoms, a history of MI at least 40 days before ICD treatment, and LVEF of 30% or less; or. 3. Nonischemic dilated cardiomyopathy and LVEF of 35% or less, after reversible causes have been excluded, and the response to optimal medical therapy, defined as 3 months of

Corporate Medical Policy - Blue Cross NC

Ischemic cardiomyopathy with New York Heart Association (NYHA) functional Class II or Class III symptoms, a history of myocardial infarction at least 40 days before ICD treatment, and left ventricular ejection fraction of 35% or less; OR Ischemic cardiomyopathy with NYHA functional Class I symptoms, a history of

Wearable Cardioverter Defibrillators

Wearable Cardioverter Defibrillators external defibrillators is extensive, ranging from in-hospital use to public access placement and home use. Its novelty is in the way that the device is packaged and utilized. Second, some evidence has suggested the device successfully terminates arrhythmias.

Are Implantable Cardioverter Defibrillator Shocks a Surrogate

The DEFINITE (Defibrillators in Non-Ischemic Cardio-myopathy Treatment Evaluation) trial was a prospective, randomized trial of ICD therapy in patients with nonischemic cardiomyopathy.8 This trial demonstrated that ICD therapy produced a decrease in SCD and a trend toward a decrease in all-cause mortality.

Prophylactic Defibrillator Implantation in Patients with

Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators* athy Treatment Evaluation (DEFINITE) trial was a prophylactic defibrillators and nonischemic dilated cardiomyopathy, of 10.